XTX Topco’s Grace Therapeutics GRCE Stock Holding History

XTX Topco’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$292K	Buy	63,094 +32,833	+108%	+$129K	0.01%	2506
2025 Q4	$106K	Buy	+30,261	New	+$96.1K	﹤0.01%	2623

Other funds holding GRCE

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

XTX Topco's GRCE Position: Q1 2026 in Review

XTX Topco increased its Grace Therapeutics (GRCE) stake by 108% in Q1 2026, buying an estimated $129K and bringing the position to 63,094 shares worth $292K. The position accounts for 0.01% of the portfolio, ranked #2506.

XTX Topco first reported a position in GRCE in Q4 2025 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

XTX Topco held 63,094 shares of Grace Therapeutics worth $292K as of Q1 2026.
XTX Topco bought 32,833 Grace Therapeutics shares in Q1 2026, an estimated $129K.
Grace Therapeutics made up 0.01% of XTX Topco's portfolio in Q1 2026, its #2506 holding.
XTX Topco first reported a position in Grace Therapeutics in Q4 2025 and has held it in 2 quarters since.
34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.